Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
- PMID: 36695823
- DOI: 10.1007/s00259-022-06100-4
Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics
Abstract
Purpose: Our aim was to assess the prognostic value of [68 Ga]Ga-FAPI-04 positron emission tomography (PET) uptake in PDAC and to evaluate the correlation between in vivo lesional radioactivity with pathological characteristics of pancreatic ductal adenocarcinoma (PDAC).
Methods: We retrospectively analyzed treatment-naïve PDAC patients who underwent preoperative [68 Ga]Ga-FAPI-04 PET/CT followed by pancreatectomy. The tracer uptake was determined as maximum tumor standardized uptake value (SUVmax), FAPI-avid tumor volume (FTV), total lesion FAP expression (TLF) as well total pancreatic uptake (TSUVmax), total FAPI-avid pancreatic volume (FPV), and total pancreatic FAP expression (TPF). Spearman's correlation analysis was performed to evaluate the association between [68 Ga]Ga-FAPI-04 PET/CT imaging and ex vivo immunohistological FAP expression and pathological characteristics of surgical specimens (differentiation, size, vascularity, perineural invasion, and lymph node metastases). Kaplan-Meier and hazard ratio (HR, log-rank) methods were used to evaluate the prognostic value of [68 Ga]Ga-FAPI-04 PET/CT and clinicopathological factors.
Results: Thirty-seven surgical PDAC patients were included. The ex vivo expression of FAP was significantly associated with the tumor SUVmax and TLF. FAP expression was more abundant in poorly differentiated PDAC than in well- to moderately differentiated neoplasms. Tumor SUVmax or TLF and pancreatic TSUVmax or TPF were significantly correlated with tumor size, differentiation, and perineural invasion, respectively. SUVmax had a significant independent prognostic value for recurrence-free survival (HR = 2.46, P < 0.05), while [68 Ga]Ga-FAPI-04 TPF predicted overall survival (HR = 12.82, P < 0.05).
Conclusion: The in vivo [68 Ga]Ga-FAPI-04 uptake in localized PDAC showed a significant correlation with ex vivo FAP expression and aggressive pathological characteristics. [68 Ga]Ga-FAPI-04 PET/CT also presented a potential for postoperative prognostication of PDAC. Elevated fibroblast activity induced by obstructive pancreatitis might be associated with the patient's survival.
Keywords: Cancer-associated fibroblast activation; Pancreatic ductal adenocarcinoma; [68 Ga]Ga-FAPI-04 PET/CT.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy.Eur J Nucl Med Mol Imaging. 2025 May;52(6):2118-2131. doi: 10.1007/s00259-025-07084-7. Epub 2025 Jan 17. Eur J Nucl Med Mol Imaging. 2025. PMID: 39820598
-
Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis.Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4036-4050. doi: 10.1007/s00259-023-06297-y. Epub 2023 Jul 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37493664
-
[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma.Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3425-3438. doi: 10.1007/s00259-023-06271-8. Epub 2023 Jun 17. Eur J Nucl Med Mol Imaging. 2023. PMID: 37328622
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities.J Nucl Med. 2023 May;64(5):711-716. doi: 10.2967/jnumed.122.264689. Epub 2022 Dec 29. J Nucl Med. 2023. PMID: 36581374 Review.
-
68Ga-FAPI-04 PET/CT for the Assessment of Light-Chain Cardiac Amyloidosis: A Promising Risk- Stratification Imaging Modality.Curr Cardiol Rep. 2025 Apr 11;27(1):83. doi: 10.1007/s11886-025-02230-x. Curr Cardiol Rep. 2025. PMID: 40214930 Review.
Cited by
-
Value of [18F]AlF-NOTA-FAPI-04 PET/CT for predicting pathological response and survival in patients with locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy.Eur J Nucl Med Mol Imaging. 2025 May;52(6):2118-2131. doi: 10.1007/s00259-025-07084-7. Epub 2025 Jan 17. Eur J Nucl Med Mol Imaging. 2025. PMID: 39820598
-
Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma.Eur J Nucl Med Mol Imaging. 2025 Jul;52(9):3075-3086. doi: 10.1007/s00259-025-07164-8. Epub 2025 Feb 28. Eur J Nucl Med Mol Imaging. 2025. PMID: 40016528
-
From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment.Cell Oncol (Dordr). 2024 Apr;47(2):361-381. doi: 10.1007/s13402-023-00872-z. Epub 2023 Sep 19. Cell Oncol (Dordr). 2024. PMID: 37726505 Review.
-
FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review.Cancer Imaging. 2023 Aug 22;23(1):79. doi: 10.1186/s40644-023-00598-z. Cancer Imaging. 2023. PMID: 37608378 Free PMC article. Review.
-
Comparison of the diagnostic accuracy between 18F-FAPI-04 PET/CT and 18F-FDG PET/CT in the clinical stage IA of lung adenocarcinoma.J Thorac Dis. 2025 Feb 28;17(2):661-675. doi: 10.21037/jtd-24-1658. Epub 2025 Feb 27. J Thorac Dis. 2025. PMID: 40083505 Free PMC article.
References
-
- Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. https://doi.org/10.1016/S0140-6736(20)30974-0 . - DOI - PubMed
-
- Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936–45. https://doi.org/10.1097/SLA.0000000000002234 . - DOI - PubMed
-
- Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. https://doi.org/10.1038/s41575-020-0300-1 . - DOI - PubMed - PMC
-
- Nicolle R, Blum Y, Marisa L, Loncle C, Gayet O, et al. Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts. Cell Rep. 2017;21(9):2458–70. https://doi.org/10.1016/j.celrep.2017.11.003 . - DOI - PubMed - PMC
-
- Madsen CD. Pancreatic cancer is suppressed by fibroblast-derived collagen I. Cancer Cell. 2021;39(4):451–3. https://doi.org/10.1016/j.ccell.2021.02.017 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
- 82071967/the National Natural Science Foundation of China
- Grant No. 2020YFC2002702/The National Key Research and Development Program of China
- CAMS-2018-I2M-3-001/Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- 2016ZX310174-4/Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- 52300300519/Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous